Tuesday, August 18, 2026
ExploreSearch
Finance Via News
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Enterprise AI Agent Rollout Outpaces Data Trust and Readiness
Enterprise adoption of agentic AI is accelerating fast — Siemens deepening its NVIDIA partnership for self-verifying agentic AI in chip design, Manulife expanding its Microsoft AI-governance partnership, and a wave of infrastructure launches (NVIDIA GPU-accelerated data processing, Dell exascale storage, new AI chip generations) — even as a new Google Cloud survey shows the underlying data foundation isn't ready: companies have AI access to only 45% of their data on average, data laggards see access fall to 30% or less, and only about half of organizations trust their AI agents' decisions. Meanwhile, insider selling at enterprise-AI bellwether C3.ai (CEO Thomas Siebel offloading $4.8M in shares) hints at investor caution layered under the adoption hype.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
JPMorgan Chase & Co.
Both facts report JPMorgan Chase & Co.'s revenue for the same fiscal period (FY 2025) with the same observation date (2025-12-31), but with different values: $182.447 billion vs. $185 billion. The ~1.4% difference ($2.553 billion) is too large to be explained by rounding alone and represents conflicting data for the identical time period.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,812
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,812 facts checked against source5,219 source documents archived
Work with this data → vianewsagency.com
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Press releaseGlobeNewswire· May 14, 2026

Senti Biosciences Holdings Announces Positive FDA RMAT Meeting on Registrational Clinical and CMC Strategy for SENTI-202 in Relapsed/Refractory AML, Along with Important Efficacy and Durability Updates on the SENTI-202 Clinical Program

View original at globenewswire.com
Senti Biosciences Holdings Announces Positive FDA RMAT Meeting on Registrational Clinical and CMC Strategy for SENTI-202 in Relapsed/Refractory AML, Along with Important Efficacy and Durability Updates on the SENTI-202 Clinical Program Following a Type B meeting with FDA, Senti Bio plans to proceed with a single-arm mu…
Opening lines of the source · GlobeNewswire · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Retrospective analysis of preclinical MV4-11 NSG mouse model data confirmed increased activity and survival with Donor X-derived SENTI-202 product; median survival was not reached for SENTI-202 NK4 group vs 56 days for vehicle

    60% confidence

  • Phase 1 patients receiving SENTI-202 from Donor X-derived NK cells achieved a 50% composite complete remission rate (7 out of 14 patients), compared to 12.5% (1 out of 8) for patients receiving non-Donor X SENTI-202

    60% confidence

  • SENTI-202 continues to exhibit durable MRD-negative responses in the full 22-patient Phase 1 trial, which compares favorably with current FDA-approved therapies for R/R AML

    60% confidence

  • SENTI-202's differentiated mechanism, off-the-shelf availability, and encouraging early clinical profile position the program as a potentially important next-generation treatment option for AML patients

    60% confidence

  • Since filing of IND, Senti has focused on donor selection to minimize variability; identification of Donor X phenotype that correlates with increased activity continues to support SENTI-202's allogeneic manufacturing

    60% confidence

  • The Donor X attribute is found in approximately 50% of adult donors; published literature supports increased NK cell cytotoxicity in donors with this phenotype; Donor X NK phenotype is independent of HLA or KIR matching, supporting allogeneic off-the-shelf usage

    60% confidence

  • The positive FDA RMAT meeting marks a transformational moment for Senti Bio and significantly advances the path toward potential registration of SENTI-202; the Gene Circuit platform and Logic Gated cell therapies are validated by this milestone

    60% confidence

  • All CR/CRh responders who were in remission at the 2025 ASH annual meeting data-cut continue to maintain remission with an additional 7 months of follow-up, with the longest duration being 21+ months

    60% confidence

  • FDA feedback provides clarity around registrational development strategy; MRD-negative durable complete remissions and favorable safety profile support confidence in transitioning to later-stage development; plans to explore expansion to newly diagnosed AML and pediatric AML

    60% confidence

  • At RP2D across all patients receiving a mix of Donor X and non-Donor X material, ORR was 44% and cCR was 37.5%, with 100% of complete remissions being MRD-negative

    60% confidence

Cited in these Via News reports